People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectivelyClosed acquisition of Greenbrook TMS effective as of December 9, 2024Expects full year 2025 pro forma ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first ... its use will be restricted to specialist clinics. The drug is the first ketamine-based medicine ...

This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

SINGAPORE: A total of 1,115 general practitioner (GP) clinics will be open at various times during the Chinese New Year period, the Ministry of Health (MOH) said on Monday (Jan 27). Of these ...